Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Featured Content 3 Undervalued Names Too Cheap to IgnoreAuthor: Nathan Reiff. Originally Published: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, with value metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits, including compelling dividends or promising product developments. While value opportunities can be harder to find when many companies have renewed investor attention — and some apparent bargains suffer from deteriorating operations or other red flags — well-established, stable names can still be attractive prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Although shares have climbed more than 28% in the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45, well below the medical industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings rise by nearly 10% in the coming year and has a 5% upside in the near term. Driving Merck's momentum is pembrolizumab (Keytruda), which was approved for subcutaneous administration by the European Commission in late 2025 and generated about $8.4 billion in sales in Q4 2025, an increase of nearly 7% year over year (YOY). Keytruda also shows promise in ovarian cancer, potentially attracting a new group of patients. These developments should help Merck continue to build revenue as it prepares for Keytruda's patent expiration in 2028. Merck's portfolio is broadening, with recent phase 3 results announced for clesrovimab-cfor (branded Enflonsia), a treatment for RSV in young children. At the same time, the company is making strategic moves ahead of Keytruda's patent loss, splitting its human health division into two units to more easily expand non–cancer-drug sales. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell’s (NASDAQ: CPB) shares have fallen about 37% over the last year as the food-and-beverage staple faced headwinds from tariffs and inflation. In Q1 fiscal 2026 (ended Nov. 2, 2025), the company reported modest YOY declines in organic net sales and consumption, with adjusted earnings per share (EPS) down 13%. The company has not yet seen notable margin improvement after initiating cost-saving measures. The near term is likely to remain challenging for the iconic brand, as fiscal-year guidance is weak overall. However, improving supply-chain operations and strong brand loyalty, especially for premium offerings, should help to protect the company. Shifts in the tariff landscape may also ease some of the pressure the company faces. On top of that, Campbell's remains an attractive dividend play, yielding about 5.9%, though its payout ratio is fairly high at over 80%. Its P/E ratio of 13.5 is the lowest in roughly four years. These factors could convince some investors that the stock is worth the risk, despite Wall Street caution. A Recent US Foods Rally May Continue, and Bottom-Line Growth Remains in Place Foodservice distributor US Foods (NYSE: USFD) saw a share-price trajectory almost opposite to Campbell's — shares have climbed about 33% in the last year. Its P/E ratio currently stands at 31.6. On fundamentals, US Foods is making meaningful progress: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% YOY. Stronger inventory management and cost-of-goods savings are helping the firm gain traction. With a $4 billion capital deployment strategy in place, US Foods is well positioned to maintain revenue momentum and continue its upward trend in adjusted EBITDA. Analysts view USFD shares as a Moderate Buy based on 11 Buys and 2 Holds, with roughly 15% upside potential.
| 
